Investigating CNTY-101’s Role in Managing Lupus and Related Conditions
The CARAMEL trial, an investigator-initiated Phase 1/2 study, will evaluate CNTY-101, a cell therapy designed for autoimmune conditions like systemic lupus erythematosus (SLE) and lupus nephritis. The study will assess its safety and efficacy in targeting B cells, central to lupus disease activity.
Unlocking New Possibilities for Parkinson’s Treatment with Stem Cell-Derived Neurons
Stem cell research is making strides in the fight against Parkinson’s disease. By using stem cells to generate dopamine-producing neurons, researchers hope to replace the neurons lost in PD and restore motor function.
